CAMP4 Therapeutics Corporation (CAMP)
Nasdaq: CAMP · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2018
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 5, 2026 | Mar 27, 2025 | · |
| Revenue | 3,498 | 652 | 350 |
| Research and development | 38,202 | 38,817 | 40,616 |
| General and administrative | 17,357 | 14,923 | 11,613 |
| Total operating expenses | 56,053 | 53,740 | 52,229 |
| Operating income | -52,555 | -53,088 | -51,879 |
| Interest and investment income | 2,174 | 1,330 | 2,808 |
| Total non-operating income (expense) | -27,848 | 1,297 | 2,588 |
| Income tax expense | 0 | 0 | 0 |
| Net income | -80,403 | -51,791 | -49,291 |
| Net income to common shareholders | -80,403 | -51,791 | · |
| Earnings per share, basic | -2.65 | -11.04 | -124.80 |
| Earnings per share, diluted | -2.65 | -11.04 | -124.80 |
| Weighted average shares, basic | 30,380,567 | 4,690,094 | 394,976 |
| Weighted average shares, diluted | 30,380,567 | 4,690,094 | 394,976 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding